MenaQ7MenaQ7® PURE is a nature-identical synthetic form of vitamin K2 as menaquinone-7 (MK-7) that matches the current draft compositional guideline for vitamin K2 in Australia.


The latest Vitamin K2 technology offered by Norwegian-based NattoPharma ASA, exclusive supplier of MenaQ7® natural and crystals. MenaQ7® PURE is an all-trans, synthetic MK-7 that is completely free of cis-isomers.


MenaQ7® natural vitamin K2 is backed by a breakthrough study demonstrating improvements in bone and cardiovascular status, and patents on cardiovascular health[BM1] .


Vitamin K is an essential bioactive compound required for optimal body function. Vitamin K2 is a versatile vitamin and has numerous functions in the body, including:

  • Regulation of osteocalcin (synthesised in bone) – a Vitamin K dependent protein associated with the mineralised matrix of bone.
  • Regulation of matrix GLa protein (synthesised in cartilage and in blood vessel walls) – a protein that inhibits vascular and soft tissue calcification when activated.
  • Regulation of bone remodelling.
  • Involvement in calcium transport, preventing calcium deposition in the lining of blood vessel walls, and helps improve bone density (additional reference).
  • Improvement in arterial stiffness in healthy postmenopausal women.
  • Vitamin K-dependent proteins are involved in regulating blood coagulation.
  • Beneficial effects on insulin sensitivity, inflammation, and blood lipid levels (reference).
  • Additional evidence is demonstrating further roles of vitamin K2 in liver conditions, immune function, neurological conditions, and obesity (reference).


Vitamin K2 is thought to be the active form of vitamin K in the bone tissue and to play a role in the maintenance of bone quality (reference). A deficiency of vitamin K2 has been linked with vascular calcification and osteoporosis (reference).


Of all the menaquinones, MenaQ7 has been found to be absorbed most efficiently and exhibits greatest bioavailability, and has a longer half-life than Vitamin K1 (reference).


A 3-year placebo-controlled trial in healthy postmenopausal women found that vitamin K2 (MenaQ7; 180 micrograms per day) significantly improved vitamin K status and decreased the age-related decline in bone mineral content and bone mineral density at the lumbar spine and femoral neck. Bone strength was favourably affected by vitamin K2. Vitamin K2 significantly decreased the loss in vertebral height of the lower thoracic region at the mid-site of the vertebrae.


Available in preparations of:

  • 1000 ppm
  • 2000 ppm
  • 1500 ppm in oil preparations


MenaQ7 can be used in tablets, capsules, and in nutritional powders (e.g. multivitamin mineral powders).


For more information, contact Craig Fallshaw at


Are you a consumer looking to buy MenaQ7?


Visit these websites to buy product:


or send us an email and we can tell you the nearest stockist to you

This is presented for informational purposes only. You should not rely on this information as a substitute or replacement for professional medical advice, diagnosis, or treatment. This website includes links to other websites. These links are provided for your convenience only and do not mean that we endorse these sites or the products and services they provide. You acknowledge and agree that we are not responsible or liable for the content or accuracy of these other sites. CMG and its staff do not claim to treat or cure any health conditions mentioned. Always read the label. Follow the directions for use. If symptoms persist, talk to your health professional.

Contact Us

  • 5a/5b Jubilee Avenue, Warriewood, NSW, 2102, Australia
  • 02 9091 0264

Request a Quote

Would you like a quote for your new product concept or talk to our sales department?

Contact: Craig Fallshaw

Teams Meeting

Contact Craig for a

Teams Meeting